Risk assessment and genetic testing for ovarian cancer

American Journal of Roentgenology

Volumn 194, Issue 2, 2010, Pages 309-310

  Gulden, Cassandra ^a   Olopade, Olufunmilayo I ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

BRCA1; BRCA2; Genetic testing; Health care policy; Ovarian cancer; Risk assessment

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ORAL CONTRACEPTIVE AGENT;

CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; EARLY MENOPAUSE; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC COUNSELING; GENETIC RISK; HEALTH CARE COST; HETEROZYGOTE; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; NOTE; OVARY CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SALPINGOOOPHORECTOMY;

FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC TESTING; HUMANS; MUTATION; OVARIAN NEOPLASMS; RISK ASSESSMENT;

EID: 76149123186     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.09.3999     Document Type: Note

References (6)

1. American Cancer Society Website. Cancer facts & figures 2009. www.cancer.org/downloads/STT/500809web.pdf. Accessed October 23, 2009
2. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104:2807-2816
3. Rebbeck TR, Lynch HT, Neuhasen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346:1616-1622
4. Rebbeck TR, Freibel T, Wagner T, et al.; PROSE Study Group. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 2005; 23:7804-7810
5. Genetic Information Nondiscrimination Act of 2008. HR 493, 110th Congress, Public Law no. 110-233
6. Leib JR, Hoodfar E, Larsen Haidle J, Nagy R. The new genetic privacy law: how GINA will affect patients seeking counseling and testing for inherited cancer risk. Commun Oncol 2008; 5:351-354 (www.communityoncology.net/ journal/articles/0506351.pdf)